Abiomed's Impella(R) Technology Showcased at ACC 2013

Thu Mar 7, 2013 8:00am EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130307:nGNXUXHVIa

DANVERS, Mass., March 7, 2013 (GLOBE NEWSWIRE) -- Abiomed Inc
http://www.globenewswire.com/newsroom/ctr?d=10024309&l=1&a=Abiomed%20Inc&u=http%3A%2F%2Fwww.abiomed.com%2F
. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, notes that there
will be over 15 Impella presentations in the scientific sessions at the annual American College of
Cardiology (ACC) 2013 scientific meeting, scheduled from March 9 - 11, at the Moscone Convention
Center in San Francisco.

On the ACC show floor, Abiomed will conduct daily booth demonstrations at Abiomed booth #N6 - 233
and hands-on simulations of the Impella platform.

For further information about the ACC program related to Impella and the timing of scientific
presentations, please contact Aimee Genzler, Corporate Communications Manager, at
agenzler@abiomed.com
http://www.globenewswire.com/newsroom/ctr?d=10024309&l=3&a=agenzler%40abiomed.com&u=mailto%3Aagenzler%40abiomed.com
 or 978-646-1553.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that
provide circulatory support. Our products are designed to enable the heart to rest by improving
blood flow and/or performing the pumping of the heart. For additional information please visit:
www.abiomed.com
http://www.globenewswire.com/newsroom/ctr?d=10024309&l=5&a=www.abiomed.com&u=http%3A%2F%2Fwww.abiomed.com%2F
.

The Abiomed logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13564
http://www.globenewswire.com/newsroom/ctr?d=10024309&l=6&u=http%3A%2F%2Fwww.globenewswire.com%2Fnewsroom%2Fprs%2F%3Fpkgid%3D13564


FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, including statements regarding development of
Abiomed's existing and new products, the Company's progress toward commercial growth, and future
opportunities and expected regulatory approvals. The Company's actual results may differ
materially from those anticipated in these forward-looking statements based upon a number of
factors, including uncertainties associated with development, testing and related regulatory
approvals, including anticipated future losses, complex manufacturing, high quality requirements,
dependence on limited sources of supply, competition, technological change, government regulation,
future capital needs and uncertainty of additional financing, and other risks and challenges
detailed in the Company's filings with the Securities and Exchange Commission, including the
Annual Report filed on Form 10-K and most recently filed Quarterly Report on Form 10-Q. Readers
are cautioned not to place undue reliance on any forward-looking statements, which speak only as
of the date of this Release. The Company undertakes no obligation to publicly release the results
of any revisions to these forward-looking statements that may be made to reflect events or
circumstances that occur after the date of this Release or to reflect the occurrence of
unanticipated events.

CONTACT: For further information please contact:
         Aimee Genzler
         Corporate Communications Manager
         978-646-1553
         agenzler@abiomed.com
         
         Susie Lisa
         Senior Director, Investor Relations, Corporate Development
         978-646-1590
         slisa@abiomed.com